Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dompe Farmaceutici S.p.A.
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 9, 2025
Management Tracks
Bayer vet Moeller to lead Antag
Plus: CMO changes at Sunbird and Cidara, and updates from Aicuris, Renovaro, Noema and more
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | May 12, 2022
Politics, Policy & Law
Russia boycott includes CAR T therapies
Behind Miltenyi Biotec’s decision to stop sales of vectors for CAR T therapy to Russia to protest war
BioCentury | May 13, 2019
Financial News
Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs
BioCentury | Apr 30, 2019
Distillery Therapeutics
Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers
BioCentury | Apr 13, 2018
Targets & Mechanisms
Meeting the burden
New developments in TMB, synthetic lethality, oncolytic viruses & more at AACR18
Items per page:
1 - 10 of 36